Cancer

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically…

3 months ago

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE)…

3 months ago

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage…

3 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success…

3 months ago

Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer

Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of…

3 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

3 months ago

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a…

3 months ago

Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical…

3 months ago

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology…

3 months ago